{
    "2018-01-08": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Novo Nordisk Makes $3.1 Billion Takeover Offer For Ablynx",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Takeover Offer",
                        "Ablynx",
                        "$3.1 Billion"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "CBMG Up 90% In 5 Days, ALDR Delivers On Promise, ABLX Being Pursued By NVO",
                "features": {
                    "keywords": [
                        "CBMG",
                        "90%",
                        "ALDR",
                        "ABLX",
                        "NVO"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Ablynx Soars After Rejects Novo Nordisk's $3.1 Billion Biotech Bid",
                "features": {
                    "keywords": [
                        "Ablynx",
                        "Soars",
                        "Rejects",
                        "Novo Nordisk",
                        "$3.1 Billion"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Novo Nordisk Revises Up Offer For Ablynx To $3.1 Billion",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Revises Up",
                        "Offer",
                        "Ablynx",
                        "$3.1 Billion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Ozempic Could Boost Novo Nordiskâ€™s Revenue Growth in 2018",
                "features": {
                    "keywords": [
                        "Ozempic",
                        "Boost",
                        "Novo Nordisk",
                        "Revenue Growth",
                        "2018"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS",
                "features": {
                    "keywords": [
                        "ABLYNX",
                        "Believes",
                        "Unsolicited Proposal",
                        "NOVO NORDISK",
                        "Undervalues",
                        "Future Prospects"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Novo Nordisk Bids $3.1 Billion For Belgian Biotech Group Ablynx",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Bids",
                        "$3.1 Billion",
                        "Belgian",
                        "Biotech",
                        "Ablynx"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Novo Goes Public With $3.1 Billion Bid To Pressure Ablynx",
                "features": {
                    "keywords": [
                        "Novo",
                        "Public",
                        "$3.1 Billion",
                        "Bid",
                        "Pressure",
                        "Ablynx"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}